-
Mashup Score: 5A Pan-Cancer Metastatic Microbiome Atlas Is Generated - 14 hour(s) ago
Major Finding: A pan-cancer resource was developed that identifies the presence and relevance of the metastatic microbiome. Approach: Multi-omic analyses were conducted on 4,160 metastatic tumors across 26 tissues to identify microbiome complexity. Impact: Characterization of the metastatic microbiome may help identify candidates for immunotherapy.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Lineage Differentiation Underlies Glioma Response to IDH Inhibition - 15 hour(s) ago
Major Finding: IDH-mutant low-grade gliomas that respond to IDH inhibition undergo lineage differentiation. Concept: Glioma cell fate is shifted towards differentiation and away from a proliferative progenitor state. Impact: This study uncovers a mechanism that may inform patient stratification strategies for glioma treatment.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
Lineage Differentiation Underlies #Glioma Response to IDH Inhibition, a summary of the study by @AvishaySpitzer, @GritschSimon, @M_Nomura, @KeithLigon5, D. Cahill, @MarioSuva, @TiroshLab et al. https://t.co/BaBrzdOaxN @WeizmannScience @MGHCancerCenter @DanaFarber @broadinstitute https://t.co/2zVPEn5nCC
-
-
Mashup Score: 40
AbstractPurpose:. The classification of small cell lung cancer (SCLC) into distinct molecular subtypes defined by ASCL1, NEUROD1, POU2F3, or YAP1 (SCLC-A, -N, -P, or -Y) expression, paves the way for a personalized treatment approach. However, the existence of a distinct YAP1-expressing SCLC subtype remains controversial.Experimental Design:. To better understand YAP1-expressing SCLC, the mutational landscape of human SCLC cell lines was interrogated to identify pathogenic alterations unique to SCLC-Y. Xenograft tumors, generated from cell lines representing the four SCLC molecular subtypes, were evaluated by a panel of pathologists who routinely diagnose thoracic malignancies. Diagnoses were complemented by transcriptomic analysis of primary tumors and human cell line datasets. Protein expression profiles were validated in patient tumor tissue.Results:. Unexpectedly, pathogenic mutations in SMARCA4 were identified in six of eight SCLC-Y cell lines and correlated with reduced SMARCA4 m
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance - 16 hour(s) ago
Summary:. Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro.See related article by Rosano et al., p. 866 (9).
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2A Single-Cell Atlas Uncovers Cellular Dynamics of the Human Breast - 19 hour(s) ago
Major Finding: Nonmalignant BRCA1/BRCA2-mutant breast tissues exhibit markers of immune infiltration and exhaustion. Approach: A single-cell atlas of the human breast maps changes influenced by age, parity, and germline mutations. Impact: This study suggests a role for immunotherapy in the prevention of BRCA1/BRCA2-mutant breast cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0OnlineFirst - 19 hour(s) ago
This site uses cookies. By continuing to use our website, you are agreeing to our privacy
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Major Finding: Anti-TRBC1 chimeric antigen receptor T-cell activity is limited by fratricide by normal TRBC1+ T cells. Concept: Development of an anti-TRBC1 antibody drug conjugate (ADC) demonstrates activity in T-cell cancers. Impact: These results suggest that this anti-TRBC1 ADC could be an attractive therapeutic candidate for T-cell cancers.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0NCI Cancer Research Data Commons: Resources to Share Key Cancer Data - 21 hour(s) ago
Abstract. Since 2014, the NCI has launched a series of data commons as part of the Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic, imaging, and clinical data to support cancer research and promote data sharing of NCI-funded studies. This review describes each data commons (Genomic Data Commons, Proteomic Data Commons, Integrated Canine Data Commons, Cancer Data Service, Imaging Data Commons, and Clinical and Translational Data Commons), including their unique and shared features, accomplishments, and challenges. Also discussed is how the CRDC data commons implement Findable, Accessible, Interoperable, Reusable (FAIR) principles and promote data sharing in support of the new NIH Data Management and Sharing Policy.See related articles by Brady et al., p. 1384, Pot et al., p. 1396, and Kim et al., p. 1404
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0OnlineFirst - 23 hour(s) ago
This site uses cookies. By continuing to use our website, you are agreeing to our privacy
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status - 1 day(s) ago
AbstractBackground:. OncotypeDx is a prognostic and predictive genomic assay used in early-stage hormone receptor–positive, HER2− (HR+/HER2−) breast cancer. It is used to inform adjuvant chemotherapy decisions, but not all eligible women receive testing. We aimed to assess variation in testing by demographics and geography, and to determine whether testing was associated with chemotherapy.Methods:. For 1,615 women in the Carolina Breast Cancer Study with HR+/HER2−, Stage I–II tumors, we estimated prevalence differences (PD) and 95% confidence intervals (CI) for receipt of OncotypeDx genomic testing in association with and sociodemographic characteristics. We assessed associations between testing and chemotherapy receipt overall and by race. Finally, we calculated the proportion of eligible women receiving OncotypeDx by county-level rurality, census tract-level socioeconomic status, and Area Health Education Center regions.Results:. 38% (N = 609) of potentially eligible women were teste
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
Read Cancer Discovery's #ResearchWatch: A Pan-Cancer Metastatic Microbiome Atlas Is Generated, summarizing the work of Thomas W. Battaglia, @IMimpen, Emile Voest et al. https://t.co/QooUBSFlik @NKI_nl https://t.co/ab0zSdScs4